Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2025. The reports are available at the SEC’s website, www.sec.gov, as well as on novonordisk.com.
Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial statements free of charge upon request to investor-relations@novonordisk.com.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information:
| Novo Nordisk Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Novo Nordisk Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com |
Max Ung +45 3077 6414 mxun@novonordisk.com |
| Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
Alex Bruce +45 3444 2613 axeu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
